Nephrolyx
Bartosz Reinhold has a diverse work experience in various roles and companies. Bartosz is currently the Chief Executive Officer at Nephrolyx and also serves as the Owner & General Manager at Kosmecki Bet GmbH (Venture Capital). Prior to this, Bartosz worked as the Managing Director at Stryker from November 2017 to January 2021. Bartosz also has experience as the CEO & Founder of Scopis GmbH from July 2010 to November 2017. Additionally, Bartosz worked at Charité as part of "The EXIST Business Start-up Grant" program from June 2009 to July 2010. Bartosz began their career as a Research Associate at Charité - University Medicine Berlin & Fraunhofer Society, where they were involved in the research and development of surgical navigation systems, specifically for ENT and Neurosurgery. Bartosz also worked at Fraunhofer-Gesellschaft as a Developer, focusing on the research and development of surgical navigation systems for ENT and Dental Implantology. Overall, Bartosz Reinhold has a strong background in executive roles, venture capital, and medical technology.
Bartosz Reinhold obtained their Master's Degree in Computer Science with a specialization in Medical Devices from Technische Universität Berlin. Bartosz pursued this degree from 2000 to 2005.
This person is not in any teams
Nephrolyx
Nephrolyx offers a precise and rapid measurement of the kidney function (true GFR). We provide hospitals and laboratories with an In-Vitro Diagnostic Test and a digital platform to measure the true GFR within only a few hours. For the first time, physicians can detect renal diseases using the highest accuracy of GFR measurement and adapt an optimal treatment plan for patients. Especially nephrology, oncology, transplantation, and ICU patients can benefit from rapid and precise diagnostics. The Nephrolyx IVDx is indicated for the in-vitro quantitative determination of serum iohexol concentration and calculation of the glomerular filtration rate (GFR). The principle of the test is based on Ultra-High-Performance-Liquid Chromatography using Ultra-Violet light. Proprietary technology from Nephrolyx helps to improve treatment success for kidney patients. Given its low component cost, the Nephrolyx IVDx can also significantly enhance the performance of the entire healthcare system.